Cargando…

715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are an important public health threat. The long-term prognosis and duration that patients harbor CRE is not well described. METHODS: We conducted a retrospective study of patients who had a culture that grew CRE within the VHA from 2016-2022. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Andrew, Ramsey, David J, Trautner, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678024/
http://dx.doi.org/10.1093/ofid/ofad500.777
_version_ 1785150267829780480
author Chou, Andrew
Ramsey, David J
Trautner, Barbara
author_facet Chou, Andrew
Ramsey, David J
Trautner, Barbara
author_sort Chou, Andrew
collection PubMed
description BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are an important public health threat. The long-term prognosis and duration that patients harbor CRE is not well described. METHODS: We conducted a retrospective study of patients who had a culture that grew CRE within the VHA from 2016-2022. For these subjects, all microbiology data was extracted from the VHA database. CRE was defined using the VHA 2019 definition: Escherichia coli, Klebsiella, Enterobacter, or Citrobacter spp. & resistant to imipenem, meropenem, or doripenem. The first CRE isolate was considered the index CRE culture, and its collection date was set as time 0 (Figure 1). Cultures within 30 days of the index CRE culture were not included in the analysis. Cultures were assigned one to the following time periods: 6 months, 1 year, 2 years, 3 years, 4 years, and after 4 years. Time periods when culture(s) grew CRE were labelled ‘R’, time periods when cultures grew bacteria that were not CRE were labelled ‘S’, time periods when no cultures were collected were labelled ‘N’, time periods during and after patient’s death were labelled ‘D’. [Figure: see text] RESULTS: We identified 8,161,898 isolates during the study period, of which 681,179 had eligible Enterobacterales. There were 4,461 CRE isolates from 2,609 unique patients. The Sankey diagram (Figure 2) shows the dynamics after the index CRE culture. At 6 months after index CRE culture, 15% of subjects still had a CRE+ culture. At 1 year and 2 years, 8% subjects still had CRE. Importantly, during each time period, study subjects steadily changed from R (grew CRE during time period) to S (grew non-CRE during time period). The rate of change from R to S remained steady throughout all time periods (range: 24% - 36%) (Table 2). The rate of re-gaining CRE (ie. status change from S to R, N to R) was low (range: 0% to 6%). The 4-year survival after the index CRE culture was 45%. [Figure: see text] R status (red nodes): CRE grew during the prior time period. N status (grey nodes): no microbiology cultures collected during prior time period. S status (blue nodes): non-CRE grew during the prior time period; D status (black nodes): patient died. Red ribbons: indicates conversion from N status to R status, or S status to R status; blue ribbons: indicates conversion from R status to S status, or N status to S status. Nodes are vertical bars at each time period (6 months, 1 year, 2 years, 3 years, 4 years, and >4 years after index CRE+ culture. Links are ribbons between nodes. [Figure: see text] [Figure: see text] N: no bacterial cultures; S: cultures without CRE; R: cultures with CRE. Percentages are the number of subjects that changed status divided by total at prior state. For example N to R: 42 (4%) means 42 subjects changed from N to R status during the time period. 4% represented the 42 subjects that changed status were out of 1,011 that started the time period in N status (42/1011 = 4%). CONCLUSION: After an index CRE culture, subjects steadily changed from R status (grew CRE during time period) to S status (grew non-CRE during time period) at the rate of 30% to 36% per year. After subjects converted to S status (grew non-CRE during time period), the rate of reversion to R status (grew CRE during time period) was 2% to 6% per year. DISCLOSURES: Andrew Chou, MD, MSc, Entasis Therapeutics: Stocks/Bonds Barbara Trautner, MD, PhD, Genentech: Grant/Research Support|Peptilogics: Grant/Research Support
format Online
Article
Text
id pubmed-10678024
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106780242023-11-27 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE Chou, Andrew Ramsey, David J Trautner, Barbara Open Forum Infect Dis Abstract BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are an important public health threat. The long-term prognosis and duration that patients harbor CRE is not well described. METHODS: We conducted a retrospective study of patients who had a culture that grew CRE within the VHA from 2016-2022. For these subjects, all microbiology data was extracted from the VHA database. CRE was defined using the VHA 2019 definition: Escherichia coli, Klebsiella, Enterobacter, or Citrobacter spp. & resistant to imipenem, meropenem, or doripenem. The first CRE isolate was considered the index CRE culture, and its collection date was set as time 0 (Figure 1). Cultures within 30 days of the index CRE culture were not included in the analysis. Cultures were assigned one to the following time periods: 6 months, 1 year, 2 years, 3 years, 4 years, and after 4 years. Time periods when culture(s) grew CRE were labelled ‘R’, time periods when cultures grew bacteria that were not CRE were labelled ‘S’, time periods when no cultures were collected were labelled ‘N’, time periods during and after patient’s death were labelled ‘D’. [Figure: see text] RESULTS: We identified 8,161,898 isolates during the study period, of which 681,179 had eligible Enterobacterales. There were 4,461 CRE isolates from 2,609 unique patients. The Sankey diagram (Figure 2) shows the dynamics after the index CRE culture. At 6 months after index CRE culture, 15% of subjects still had a CRE+ culture. At 1 year and 2 years, 8% subjects still had CRE. Importantly, during each time period, study subjects steadily changed from R (grew CRE during time period) to S (grew non-CRE during time period). The rate of change from R to S remained steady throughout all time periods (range: 24% - 36%) (Table 2). The rate of re-gaining CRE (ie. status change from S to R, N to R) was low (range: 0% to 6%). The 4-year survival after the index CRE culture was 45%. [Figure: see text] R status (red nodes): CRE grew during the prior time period. N status (grey nodes): no microbiology cultures collected during prior time period. S status (blue nodes): non-CRE grew during the prior time period; D status (black nodes): patient died. Red ribbons: indicates conversion from N status to R status, or S status to R status; blue ribbons: indicates conversion from R status to S status, or N status to S status. Nodes are vertical bars at each time period (6 months, 1 year, 2 years, 3 years, 4 years, and >4 years after index CRE+ culture. Links are ribbons between nodes. [Figure: see text] [Figure: see text] N: no bacterial cultures; S: cultures without CRE; R: cultures with CRE. Percentages are the number of subjects that changed status divided by total at prior state. For example N to R: 42 (4%) means 42 subjects changed from N to R status during the time period. 4% represented the 42 subjects that changed status were out of 1,011 that started the time period in N status (42/1011 = 4%). CONCLUSION: After an index CRE culture, subjects steadily changed from R status (grew CRE during time period) to S status (grew non-CRE during time period) at the rate of 30% to 36% per year. After subjects converted to S status (grew non-CRE during time period), the rate of reversion to R status (grew CRE during time period) was 2% to 6% per year. DISCLOSURES: Andrew Chou, MD, MSc, Entasis Therapeutics: Stocks/Bonds Barbara Trautner, MD, PhD, Genentech: Grant/Research Support|Peptilogics: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10678024/ http://dx.doi.org/10.1093/ofid/ofad500.777 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Chou, Andrew
Ramsey, David J
Trautner, Barbara
715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title_full 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title_fullStr 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title_full_unstemmed 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title_short 715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE
title_sort 715. dynamic gain and loss of carbapenem-resistant enterobacterales by vha patients during 2016-2022: loss of cre exceeds gain of cre
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678024/
http://dx.doi.org/10.1093/ofid/ofad500.777
work_keys_str_mv AT chouandrew 715dynamicgainandlossofcarbapenemresistantenterobacteralesbyvhapatientsduring20162022lossofcreexceedsgainofcre
AT ramseydavidj 715dynamicgainandlossofcarbapenemresistantenterobacteralesbyvhapatientsduring20162022lossofcreexceedsgainofcre
AT trautnerbarbara 715dynamicgainandlossofcarbapenemresistantenterobacteralesbyvhapatientsduring20162022lossofcreexceedsgainofcre